Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Teva Pharmaceutical Industries Limited < Previous 1 2 3 4 5 Next > New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses June 28, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020 June 25, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States June 24, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) June 01, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 June 01, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) May 29, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. May 20, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers ALVO TEVA Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations May 15, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook May 08, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia May 08, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present at the 2024 Bank of America Healthcare Conference May 02, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets May 02, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers ALVO TEVA Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers ALVO TEVA Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 April 09, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 April 06, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate April 04, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement April 01, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers CG TEVA Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China February 26, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® February 23, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers ALVO TEVA Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting February 20, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports Growth in Fourth Quarter and Full Year 2023 January 31, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy January 31, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024 January 02, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 28, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma December 14, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity December 06, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.